Welcome to our dedicated page for Keros Therapeutics SEC filings (Ticker: KROS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Keros Therapeutics, Inc. (Nasdaq: KROS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Keros’ clinical programs, capital allocation decisions, governance changes and financial condition.
As a clinical-stage biopharmaceutical company focused on TGF-ß pathway therapeutics, Keros uses its SEC filings to report material events related to its lead product candidate KER-065 and its most advanced candidate elritercept. Form 8-K reports have covered topics such as additional clinical data from a Phase 1 trial of KER-065, U.S. Food and Drug Administration Orphan Drug designation for KER-065 in Duchenne muscular dystrophy, and corporate updates regarding the prioritization of KER-065 and discontinuation of internal development of cibotercept (KER-012).
Filings also document Keros’ capital return program and share repurchase activity. Recent 8-Ks describe stock purchase agreements with entities affiliated with ADAR1 Capital Management and Pontifax Venture Capital, the planned and completed cash tender offer to repurchase a substantial number of shares of common stock at a fixed price, and related governance changes. Other reports furnish quarterly financial results, including revenue from a global license agreement with Takeda Pharmaceuticals U.S.A., Inc. related to elritercept, research and development spending and cash and cash equivalents.
On this page, users can review real-time updates as new KROS filings are posted to EDGAR, including Forms 8-K, 10-Q and 10-K when available, as well as exhibits such as press releases and corporate presentations. Stock Titan’s AI-powered tools summarize lengthy filings, highlight key sections and help explain complex topics like capital return structures, executive employment agreements and risk factor disclosures in more accessible language.
For those analyzing Keros’ development strategy, financial runway, licensing arrangements or governance, the SEC filings page serves as a primary source of company-sanctioned information. It allows investors and researchers to trace how Keros reports progress on its TGF-ß–focused pipeline, documents material agreements and communicates significant corporate events over time.
Keros Therapeutics, Inc. furnished an updated corporate presentation for use in meetings with investors, analysts and others. The company made this updated presentation available on its website and also attached it as Exhibit 99.1 to this current report. The presentation is dated January 2026 and is meant to provide additional background on the business.
The company states that the information in this report, including Exhibit 99.1, is being furnished under Regulation FD and is not considered filed for purposes of certain liability provisions of the Securities Exchange Act. It will only be incorporated into other securities filings if specifically referenced there.
Keros Therapeutics CEO Jasbir Seehra reported a performance-based stock option update. On January 7, 2026, he was credited with 62,500 employee stock options with an exercise price of
The original grant, reported in February 2024, covered options for 125,000 shares subject to performance goals. The committee determined that targets tied to 62,500 shares were achieved, causing 31,250 shares to vest immediately and scheduling another 31,250 to vest on
Keros Therapeutics, Inc. director-affiliated investment entities reported selling common stock in connection with the company’s completion of a cash tender offer. OrbiMed-related funds disposed of 140,057 shares and 74,465 shares of Keros common stock at a price of $17.75 per share on 11/21/2025. Following these transactions, one OrbiMed fund reported indirect beneficial ownership of 759,155 shares, and another reported 45,057 shares, while the reporting entities each disclaim beneficial ownership beyond their pecuniary interest.
Keros Therapeutics director Carl L. Gordon reported indirect sales of Keros Therapeutics, Inc. common stock in connection with the company’s completion of a cash tender offer. On 11/21/2025, 140,057 shares of common stock were disposed of at $17.75 per share, leaving 759,155 shares beneficially owned indirectly. On the same date, an additional 74,465 shares were disposed of at $17.75 per share, leaving 45,057 shares beneficially owned indirectly.
The shares are held through OrbiMed-affiliated investment entities, including OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P. Various OrbiMed general partners and OrbiMed Advisors LLC may be deemed to share voting and investment power over these holdings, but each related entity and person, including the reporting person, disclaims beneficial ownership beyond any pecuniary interest.
Keros Therapeutics, Inc. director reported share dispositions tied to the company’s cash tender offer. On 11/21/2025, the reporting person tendered 191,527 shares of common stock at $17.75 per share and separately tendered 130,494 shares at $17.75 per share, as noted in footnote (1) describing an issuer cash tender offer that began on October 20, 2025 and whose final results were announced on November 20, 2025. Following these transactions, the director beneficially owns 150,047 shares indirectly through Partners Innovation Fund, LLC, 102,233 shares indirectly through Partners Innovation Fund II, L.P., and 6,441 shares directly.
Keros Therapeutics, Inc. filed Amendment No. 2 to its Schedule TO, updating its issuer tender offer to repurchase up to 10,950,165 shares of common stock for a total of up to $194.4 million at $17.75 per share in cash, before taxes and without interest. The offer is being made under an Offer to Purchase and related Letter of Transmittal.
The amendment notes that on November 20, 2025 the company issued a press release announcing the final results of the tender offer, which expired at 5:00 p.m. New York City time on November 18, 2025, and files that press release as a new exhibit.
Keros Therapeutics, Inc. filed Amendment No. 1 to its Schedule TO for an issuer tender offer to repurchase up to 10,950,165 shares of its common stock for an aggregate purchase price of up to $194.4 million at $17.75 per share in cash, less any applicable withholding taxes and without interest. The offer is being made under an Offer to Purchase and Letter of Transmittal previously filed with the SEC.
The amendment updates additional information by noting that on November 19, 2025, Keros issued a press release announcing the preliminary results of the tender offer, which expired at 5:00 p.m., New York City time, on November 18, 2025. The press release is filed as a new exhibit and incorporated by reference.
Keros Therapeutics (KROS) filed its Q3 2025 report showing revenue of $14.3 million, driven by $10.0 million of license revenue and $4.3 million of service and other revenue. For the first nine months, revenue reached $243.7 million, reflecting the $200.0 million upfront from Takeda and a $10.0 million milestone after the first patient was dosed in the Phase 3 RENEW trial.
The company posted a Q3 net loss of $7.3 million, but delivered $110.5 million of net income year-to-date as licensing gains offset operating costs. Cash and cash equivalents were $693.5 million as of September 30, 2025. Operating expenses eased: research and development was $111.7 million year-to-date versus $128.0 million a year ago, aided by a workforce reduction plan (estimated $3.1 million in restructuring costs).
Keros advanced elritercept (KER-050) into Phase 3 under its Takeda agreement and plans a Phase 2 trial for KER-065 in Duchenne muscular dystrophy. Capital return actions included repurchasing 10,176,595 shares for $180.6 million at $17.75 per share and commencing an issuer tender offer of up to $194.4 million at the same price. Shares outstanding were 30,466,069 as of October 31, 2025.
Keros Therapeutics (KROS)Item 2.02 report stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference. The company notes the information is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor otherwise subject to that section’s liabilities. Securities listed include common stock on Nasdaq under KROS and preferred share purchase rights.
Keros Therapeutics (KROS) launched an issuer tender offer to repurchase up to 10,950,165 shares of its common stock for cash at $17.75 per share, for an aggregate purchase price of up to $194.4 million. The offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase and related Letter of Transmittal, and will be effected with proration, withdrawal rights, and other standard tender mechanics.
The company is the buyer in this transaction and will pay cash to tendering stockholders, less any applicable withholding taxes and without interest. Shares outstanding were 30,466,069 as of October 17, 2025; this is a baseline figure, not the amount being purchased.
FAQ
What is the current stock price of Keros Therapeutics (KROS)?
What is the market cap of Keros Therapeutics (KROS)?
